Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
309 results about "Angiotensin II" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Active form of angiotensin; an octapeptide found in blood, it is synthesized from angiotensin I and quickly destroyed; angiotensin II causes profound vasoconstriction with a resulting increase in blood pressure; it differs among species by the amino acid in position 5.
Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
InactiveUS20110082119A1Slow downGood treatment effectBiocideAntipyreticNonsteroidal Antiinflammatory Drugs/NSAIDsBULK ACTIVE INGREDIENT
A highly safe and effective prophylactic / ameliorating or therapeutic agent for NACH and the method for using the same are provided.A prophylactic / ameliorating or therapeutic agent for NASH containing a combination of at least one first ingredient selected from the group consisting of an ω3PUFA and pharmaceutically acceptable salts and esters thereof and at least one second ingredient selected from the group consisting of (a) a biguanide hypoglycemic agent, (b) a nonsteroidal anti-inflammatory drug, (c) a 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor, and (d) an angiotensin II receptor blocker as the active ingredients; and its method of use.
Owner:MOCHIDA PHARM CO LTD
Use of angiotensin II receptor antagonists
InactiveUS20050070594A1Lower Level RequirementsGood blood pressureBiocideMetabolism disorderBlood pressurePrediabetes
The invention relates to the use of angiotensin II receptor antagonists for treating people in whom type 2 diabetes mellitus has been diagnosed or who are suspected of prediabetes, for preventing diabetes or for treating metabolic syndrome and insulin resistance in patients with normal blood pressure.
Owner:BOEHRINGER INGELHEIM INT GMBH
Preparation method for dual inhibitor LCZ696 of angiotensin II receptor and neprilysin
InactiveCN105168205AQuality improvementHigh purityOrganic compound preparationCarboxylic acid amides preparationValsartanHigh volume manufacturing
The invention specifically relates to a preparation method for a dual inhibitor LCZ696 of angiotensin II receptor and neprilysin, which belongs to the technical field of drug synthesis. The preparation method comprises the following steps: preparing valsartan and AHU-377 or AHU-377 calcium salt at first; and then mixing valsartan with AHU-377 or AHU-377 calcium salt under stirring so as to prepare LCZ696. The LCZ696 prepared in the invention has good quality and high purity; and the preparation method has the advantages of simplicity, low energy consumption, low cost and suitability for large batch production.
Owner:TAILITE MEDICINE HUBEI
Treatment of Prevention of Unscheduled Bleeding in Women on Progestogen Containing Medication
InactiveUS20090197843A1Increased chronotropismIncreased inotropismBiocidePeptide/protein ingredientsPhysiologyProgestogen
The present invention relates to a method of treating or preventing unscheduled bleeding in women, the unscheduled bleeding being the result of repeated administration of a hormonal composition that contains a progestogen, wherein the method includes the administration of an effective amount of Renin Angiotensin System (RAS) suppressor selected from angiotensin converting enzyme inhibitors; angiotensin II receptor antagonists; renin inhibitors and combinations thereof. Other aspects of the invention relate to a pharmaceutical composition containing a RAS suppressor and a progestogen and to a pharmaceutical kit having a plurality of dosage units, wherein at least one dosage unit contains a progestogen; at least one dosage unit contains an estrogen; and at least one dosage unit contains a RAS suppressor.
Owner:PANTARHEI BIOSCI
Imidazo-5-carboxylic-acid derivatives, its preparing method and use
The invention discloses an imidazole-5-carboxylic acids derivative and the manufacturing method. It is the angiotensin II acceptor antagon. It has strong angiotensin II antagonize activity and high blood pressure proofing activity. And it could be used as therapeutic agent to cure high blood pressure.
Owner:SHANGHAI ALLIST PHARM CO LTD
Method of treatment and/or prophylaxis
InactiveUS20030199424A1Easy to prepareHigh viscosityHeavy metal active ingredientsBiocideVertebrate AnimalsPsychiatry
The present invention is directed to the use of angiotensin II receptor I (AT1 receptor) antagonists for the treatment, prophylaxis, reversal and / or symptomatic relief of a neuropathic condition, especially a peripheral neuropathic condition such as painful diabetic neuropathy, in vertebrate animals and particularly in human subjects. The present invention also discloses the use of AT1 receptor antagonists for preventing, attenuating or reversing the development of reduced opioid sensitivity, and more particularly reduced opioid analgesic sensitivity, in individuals and especially in individuals having, or at risk of developing, a neuropathic condition.
Owner:QUEENSLAND UNIV OF
Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
InactiveUS20090137556A1Reduced gene expressionIncrease gene expressionAntibacterial agentsBiocideDermatological disordersACE Inhibitor Fetopathy
In one aspect, the present invention relates to use of an ACE inhibitor and / or angiotensin II receptor antagonist for the preparation of a medicament for the treatment of a dermatological disorder, particularly by topical application of said ACE inhibitor and / or angiotensin II receptor antagonist. The present invention also provides cosmetic methods for improving and / or maintaining the skin tone of an individual suffering from, or at risk of suffering from, a dermatological disorder, said method comprising contacting the skin of said individual with an ACE inhibitor and / or angiotensin II receptor antagonist.
Owner:ACE APS
Pharmaceutical composition for treating hypertension and cardiovascular disease
InactiveCN1883478AImprove solubilityImprove bioavailabilityPill deliveryGranular deliveryVascular diseaseTreatment effect
Owner:CSPC OUYI PHARM CO LTD
Sustained-release preparation for AII antagonist, production and use thereof
InactiveUS6589547B1Reduce the amount of solutionControlled release ratePowder deliveryOrganic active ingredientsBlood pressureCircadian rhythm
The present invention is to provide a sustained-release preparation which comprises a compound having angiotensin II antagonistic activity, its pro-drug or their salt, and a biodegradable polymer, and if necessary, a polyvalent metal, and which is highly stable and active and shows angiotensin II antagonistic activity while maintaining circadian rhythm of blood pressure for a long time.
Owner:TAKEDA PHARMA CO LTD
Heterocyclic compounds and their use as angiotensin antagonists
InactiveUS6100252AHigh yieldPotent angiotensin II receptor antagonistic activityBiocideNervous disorderDiseaseHeart disease
Compounds shown by the above formula or salt thereof show a strong angiotensin II antagonistic activity and hypotensive action and CNS activity, and are useful as therapeutic agents of circulatory diseases such as hypertensive diseases and heart diseases (e.g. hypercardia, heart failure, cardiac infarction), strokes, cerebral apoplexy, nephritis, atherosclerosis, Alzheimer's disease, senile dementia, etc.
Owner:TAKEDA PHARMACEUTICALS CO LTD
Method of Treating Low Blood Pressure
ActiveUS20110144026A1Lower blood pressurePeptide/protein ingredientsCardiovascular disorderCardiorespiratory arrestLow blood pressures
A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.
Owner:THE GEORGE WASHINGTON UNIV A CONGRESSIONALLY CHARTERED NOT FOR PROFIT CORP
Use of angiotensin ii agonists
InactiveUS20120035232A1High expressionPromoting reinnervationOrganic active ingredientsBiocideMedicineAgonist
There is provided a compound of formula I,wherein Y1, Y2, Y3, Y4, Z1, Z2, R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, for use in the treatment of spinal cord injury.
Owner:VICORE PHARMA AB
Angiotensin peptide-carrier conjugates and uses thereof
InactiveUS7115266B2Promote formationImprove complianceVirusesPeptide/protein ingredientsVirus-like particleAngiotensinogen mrna
The present invention provides conjugates of peptide derivatives of the mammalian peptide hormones angiotensinogen, angiotensin I and angiotensin II, presented in a repetitive scaffold by coupling the peptide derivatives to a carrier, particularly a virus-like particle (VLP). The invention also provides methods of producing such conjugates, and immunotherapeutic uses of the resulting immunogen conjugates for the therapy and prophylaxis of conditions associated with the renin-activated angiotensin system.
Owner:CYTOS BIOTECHNOLOGY AG
Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
InactiveUS7118748B1Increasing hematopoietic cell survivalReducing and preventing side effectPeptide/protein ingredientsGenetic material ingredientsCell culture mediaAngiogenesis growth factor
The present invention provides methods, improved cell culture medium and kits for promoting hematopoietic and mesenchymal stem and lineage-specific cell proliferation and differentiation by growth in the presence of angiotensinogen, angiotensin I (Al), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists, either alone or in combination with other growth factors and cytokines.
Owner:UNIV OF SOUTHERN CALIFORNIA
Pharmaceutical composition for angiotensin II-mediated diseases
InactiveUS6348481B2Undesirable side-effectRemarkable effectBiocideOrganic chemistryDiseaseDiuretic Activity
This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formulawherein R1 is H or an optionally substituted hydrocarbon residue; R2 is an optionally esterified carboxyl group; R3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R2; and Y is a bond, -O-, -S(O)m- (wherein m is 0, 1 or 2) or -N(R4)- (wherein R4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.
Owner:TAKEDA PHARMA CO LTD
Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
InactiveUS20050272649A1Preventing delaying needReducing necessary frequencyBiocidePeptide/protein ingredientsRenal disorderMorphine
The present invention provides reagents and methods for the treatment, and pharmaceuticals for use in the prevention and / or treatment, of chronic renal failure and other renal disorders in subjects (particularly mammalian subjects) renal replacement therapy. The methods involve the conjoint administration of ACE (Angiotensin-Converting Enzyme) inhibitors or Angiotensin II Receptor Antagonists (AIIRAs) with one or more OP / BMP family of proteins (morphogens, or inducers of morphogens, or agonists of the corresponding morphogen receptors, etc.). The invention also provides methods for implantation of renal cells induced with the conjoint administration of ACE inhibitors or AIIRAs with those morphogens.
Owner:BARNES JEWISH HOSPITAL +1
Wound healing compositions
Methods and compositions based on chemical analogs of angiotensin II and analogs of angiotensin II fragments useful for accelerating wound healing in mammals.
Owner:UNIV OF SOUTHERN CALIFORNIA
Methods for accelerating bone and cartilage growth and repair
InactiveUS6916783B2Strengthen bonesEnhancing cartilage repairAngiotensinsPeptide/protein ingredientsProsthesis ImplantationAgonist
The present invention provides improved methods, kits, and compositions for enhancing bone, cartilage and cartilage repair, bone and prosthesis implantation, and attachment and fixation of cartilage and cartilage to bone or other tissues, and chondrocyte proliferation composing the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists.
Owner:UNIV OF SOUTHERN CALIFORNIA
Methods for inhibiting tumor cell proliferation
InactiveUS7122523B2Inhibit cell proliferationAngiotensinsPeptide/protein ingredientsGynecologyAgonist
The present invention provides methods, compounds, and pharmaceutical compositions for inhibiting tumor cell proliferation, by administering an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists to a subject.
Owner:SOUTHERN CALIFORNIA UNIV OF THE +1
Compositions and Methods for Treating Renal Failure
ActiveUS20140329747A1Good blood pressurePositive responseHormone peptidesOrganic active ingredientsFAILURE KIDNEYRenal Failures
The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.
Owner:LA JOLLA PHARMA LLC
PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effective amount of a compound sufficient to partially or fully activate peroxisome proliferator activated receptors (PPARs) and partially or fully inhibit, antagonize or block the activity of angiotensin II type 1 receptors. Metabolic disorders that can be treated or prevented include but are not limited to type 2 diabetes, the metabolic syndrome, prediabetes, and other insulin resistance syndromes. Compounds are provided that antagonize or block the angiotensin II type 1 (AT1) receptor, function as partial or full activators of peroxisome proliferator activated receptors (PPARs), can be used to treat or prevent diseases known to be treatable or preventable by PPAR activators and were not previously recognized to be therapeutic targets for angiotensin II receptor antagonists.
Owner:BETHESDA PHARMA
Compositions comprising novel PPAR ligands and anti-hyperlipemic agents
InactiveUS20070054949A1Convenient treatmentPrevent goodBiocideAntipyreticDyslipidemiaTG - Triglyceride
Methods are provided for treating or preventing conditions comprising hypertension and dyslipidemia using antihyperlipemic agents and compounds that antagonize the angiotensin II type 1 (AT1) receptor, function as partial or full activators of peroxisome proliferator activated receptors (PPARs) and lower triglycerides or elevate blood HDL-cholesterol. Compositions are provided for treating or preventing conditions comprising hypertension and dyslipidemia, comprising antihyperlipemic agents which lower triglycerides and inhibit cholesterol synthesis such as statins, and compounds that antagonize or block the angiotensin II type 1 (AT1) receptor, activate PPARs and lower triglycerides or elevate blood HDL-cholesterol such as sartans.
Owner:BETHESDA PHARMA
Methods for breast cancer screening and treatment
InactiveUS20100029734A1Decreasing Ang II-induced cell proliferationPromote growthBiocideDisease diagnosisBreast cancer screeningACE Inhibitor Fetopathy
A method for selecting a breast cancer patient for therapy with an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor, comprises (a) determining whether the cancer comprises a tumor that is estrogen receptor positive (ER+) and (b) selecting the patient for such therapy only if the cancer is determined to comprise an ER+ tumor. A method for treating breast cancer in a patient further comprises (c) administering to the patient, if so selected, an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor. A method for treating a breast tumor in a patient having SERM-resistant ER+ breast cancer comprises administering to the patient an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor. A therapeutic combination useful in treatment of a breast tumor comprises an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor, and a second agent that comprises (a) an aromatase inhibitor or (b) an estrogen receptor modulator or antagonist.
Owner:ORE PHARMA
Method for treating resistant hypertension
A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.
Owner:MYOGEN INC +1
Medicinal composition of calcium-containing antagonist, A II receptor antagonist and statins
The invention relates to a medicinal composition, which consists of the following parts: a calcium ion antagonist (CCB) or pharmaceutically acceptable salt thereof, an angiotensin II acceptor antagonist (ARB) or pharmaceutically acceptable salt or ester thereof, statins or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention also relates to a combined kit containing the active substances. The medicinal composition or the kit is used for treating hypertension, dyslipidemia, cerebrovascular disorder, stroke, coronary heart disease, diabetes, diabetic complication, angina, myocardial infarction, cardiac insufficiency, renal dysfunction, atherosclerosis, ventricular hypertrophy, aneurysm, myocardial ischemia, arrhythmia and glaucoma of patients, reducing the incidence rate and / or the death rate of cardiovascular and cerebrovascular disease, improving the adaptability of drug administration of the patients at the same time, and improving the life quality of the patients.
Owner:王丽燕
Pharmaceutical composition for angiotensin II-mediated diseases
InactiveUS20010011098A1Undesirable side-effectRemarkable effectBiocideOrganic chemistryDiuretic ActivityDisease
This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula wherein R1 is H or an optionally substituted hydrocarbon residue; R2 is an optionally esterified carboxyl group; R3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R2; and Y is a bond, -O-, -S(O)m- (wherein m is 0, 1 or 2) or -N(R4)- (wherein R4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.
Owner:TAKEDA PHARMA CO LTD
Angiotensin II alone or in combination for the treatment of hypotension
The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg / kg / min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg / kg / min norepinephrine or less, or to the equivalent of about 0.05 mcg / kg / min norepinephrine or less.
Owner:THE GEORGE WASHINGTON UNIV A CONGRESSIONALLY CHARTERED NOT FOR PROFIT CORP
Angiotensin peptide-carrier conjugates and uses thereof
InactiveUS20060078554A1Promote antibody formationPromote formationVirusesHydrolasesVirus-like particleAngiotensinogenase
The present invention provides conjugates of peptide derivatives of the mammalian peptide hormones angiotensinogen, angiotensin I and angiotensin II, presented in a repetitive scaffold by coupling the peptide derivatives to a carrier, particularly a virus-like particle (VLP). The invention also provides methods of producing such conjugates, and immunotherapeutic uses of the resulting immunogen conjugates for the therapy and prophylaxis of conditions associated with the renin-activated angiotensin system.
Owner:CYTOS BIOTECHNOLOGY AG
Compositions and methods of treating hypertension with tannin complexes
InactiveUS20090118202A1Lower Level RequirementsInhibit transcriptionBiocideCarbohydrate active ingredientsTanninTannic acid
The present invention includes methods and compositions to ameliorate one or more symptom of hypertension through the inhibitor of an AT1 receptor by transcriptional down regulation of an angiotensin II type 1 receptor. The composition includes an effective amount of one or more tannic acids disposed in a pharmaceutically acceptable carrier.
Owner:TEXAS TECH UNIV SYST
Method for predicting angiotonin II receptor agonist hypotensor function and use
ActiveCN1858240BImprove efficiencyImprove securityMicrobiological testing/measurementSide effectGenotype
Owner:SHENZHEN AUSA PHARM CO LTD +3
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com